![]() ![]() Under HERA Invest, the European Investment Bank (EIB) will provide venture loans, covering a maximum of 50% of total project costs. Chemical, biological, radiological and nuclear threats originating from accidental or deliberate release.Pathogens with pandemic or epidemic potential.The HERA Invest funding instrument is geared towards small and mid-sized companies (SMEs) that develop medical countermeasures addressing one of the following health threats: ![]() creating new medical countermeasures to protect against health threats.leveraging public funding to incentivise private investment.reducing market failures, where financial resources do not cover the financing needs.promoting R&D in Europe to strengthen strategic autonomy.HERA Invest, a flagship initiative of the European Health Emergency Preparedness and Response Authority, will focus on health emergency prevention and preparedness, helping address these challenges by: Innovation is needed to respond to priority health threats such as pathogens with high pandemic potential or resistance to antibiotics. ![]() Currently, European companies find it difficult to access sufficient public and private funding for the development and scaling up of cutting-edge solutions in health and life sciences. ![]() Today, the Commission and the European Investment Bank announce the creation of HERA Invest, a € 100 million top-up to the InvestEU programme, to support research and development (R &D) in the most pressing cross-border health threats, financed by the EU4Health programme.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |